|
⚲
|
| Keyboard |
| Morgan Stanley AIP GP LP
✚
|
|
|---|---|
| CRD # | 117050 |
| SEC # | 801-60699 |
| CIK # | 0001230207 |
| AUM | 40.85 B (2026-03-30) |
| Employees | 200 (84% Investors, 14% Brokers) |
| Fees | |
| Minimum | |
| Phone | 610-260-7600 |
| Address | 100 Front Street West Conshohocken, PA 19428 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($T) | |
|---|---|---|---|
| Apple Inc | 0.1 | ||
| Nvidia Corp | 0.1 | ||
| Microsoft Corp | 0.0 | ||
| Amazon Com Inc | 0.0 | ||
| Alphabet Inc | 0.0 | ||
| Broadcom Inc | 0.0 | ||
| Facebook Inc | 0.0 | ||
| Alphabet Inc | 0.0 | ||
| J P Morgan Chase & Co | 0.0 | ||
| Tesla Motors Inc | 0.0 | ||
| View All | |||
| Holdings by Sector ($T) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| Other | Hedge Fund Core Primaries Series 1 A Series of Riverview Multi-Client Solutions Fund LP | [2026-03-30] | 89.5 M | 96.1 M |
| Filed 2026-01-16 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| Other | Montserrat Fund Cayman LP | 2026-03-30 | 53.5 M | |
| Other | Orion Private Equity Partners Fund LP | [2026-03-30] | 11.0 M | |
| Filed 2025-04-14 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $250,000 · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| Other | Riverview Alpha Strategies Q AIV LP | 2026-03-30 | 204.7 M | |
| Other | Riverview Alpha Strategies Q LP | 2026-03-30 | 374.0 M | |
| Other | Tandem SPV LP | 2026-03-30 | 127.8 M | |
| PE | 1GT Fund LP | [2025-03-28] | 25.7 M | |
| Filed 2023-12-15 (D) · Exemption 506(c), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Commission $750,000 · Net Assets Decline to Disclose | ||||
| Other | North Haven Ashbridge Co-Investment Opportunity B LP | [2025-03-28] | 64.1 M | |
| Filed 2024-10-04 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| Other | North Haven Private Equity Co-Investment Opportunities Fund III Splitter Lux SCSP | [2025-03-28] | 87.6 M | |
| Filed 2024-05-15 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $225,000 · Net Assets Decline to Disclose | ||||
| Other | PSG Private Credit LP | [2025-03-28] | 300.6 M | 71.7 M |
| Filed 2024-07-18 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 16 | 0.5 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 4 | 2.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 124 | 32.4 |
| (g) Pension and profit sharing plans | 4 | 0.8 |
| (h) Charitable organizations | 8 | 0.2 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 2 | 0.0 |
| (k) Insurance companies | 1 | 0.7 |
| (l) Sovereign wealth funds and foreign official institutions | 3 | 0.3 |
| (m) Corporations or other businesses not listed above | 36 | 4.0 |
| (n) Other | 1 | 0.0 |
| Total | 199 | 40.9 |
| By Discretionary | ||
| Discretionary | 184 | 40.1 |
| Non-Discretionary | 15 | 0.8 |
| Total | 199 | 40.9 |
| By Non-United States Persons | ||
| Non-United States Persons | 14.9 | |
| United States Persons | 25.9 | |
| Total | 199 | 40.9 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Charles Thomas | Director | 160 | 30 | |
| Campbell Congdon | Director | 179 | 28 | |
| Jason Sneah | Director, Executive Officer | 189 | 25 | |
| Tim Woolaver | Director | 90 | 25 | |
| Khalid Iton | Director, Executive Officer | 109 | 22 | |
| Peter Huber | Director | 88 | 22 | |
| Sam Ellis | Director | 106 | 18 | |
| Wendy Zhang | Director | 46 | 15 | |
| David Miller | Director | 298 | 14 | |
| Stephane Lachance | Director | 143 | 14 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-NT | [0001230207] | |
| 3 | [0001230207] | |
| 4 | [0001230207] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $4.9B |
| Serves | Institutional, Retail |
| Fund Types | Hedge Fund, Private Equity, Real Estate |
| LEI | 549300KSRL5W75JNE398 |
| Related People Network |
|---|
| 206 people file Form D offerings alongside this firm's people, tied to 24 other firms through shared filers. |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Morgan Stanley AIP GP LP | |
| North Haven Private Assets Fund | |
| Morgan Stanley Investment Management Inc | |
| Sagent Pharmaceuticals Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Sagent Pharmaceuticals Inc SGNT
Common Stock
|
2015-01-27 | Sell | 50,000 | $26.19 | 1,309,500 |
|
Sagent Pharmaceuticals Inc SGNT
Common Stock
|
2015-01-26 | Sell | 28,041 | $26.12 | 732,431 |
|
Sagent Pharmaceuticals Inc SGNT
Common Stock
|
2015-01-23 | Sell | 61,883 | $25.90 | 1,602,770 |
|
Sagent Pharmaceuticals Inc SGNT
Common Stock
|
2015-01-22 | Sell | 150,000 | $25.49 | 3,823,500 |
|
Sagent Pharmaceuticals Inc SGNT
Common Stock
|
2015-01-21 | Sell | 44,316 | $25.22 | 1,117,650 |
|
Sagent Pharmaceuticals Inc SGNT
common stock
|
2015-01-20 | Sell | 25,000 | $25.24 | 631,000 |
|
Sagent Pharmaceuticals Inc SGNT
Common Stock
|
2015-01-16 | Sell | 50,000 | $25.26 | 1,263,000 |
|
Sagent Pharmaceuticals Inc SGNT
Common Stock
|
2015-01-15 | Sell | 75,000 | $25.10 | 1,882,500 |
|
Sagent Pharmaceuticals Inc SGNT
Common Stock
|
2015-01-14 | Sell | 50,000 | $25.53 | 1,276,500 |
|
Sagent Pharmaceuticals Inc SGNT
Common Stock
|
2015-01-13 | Sell | 50,000 | $25.49 | 1,274,500 |
|
Sagent Pharmaceuticals Inc SGNT
Common Stock
|
2013-10-03 | Sell | 47,826 | $20.27 | 969,433 |
|
Sagent Pharmaceuticals Inc SGNT
Common Stock
|
2013-10-02 | Sell | 40,020 | $20.32 | 813,206 |
|
Sagent Pharmaceuticals Inc SGNT
Common Stock
|
2013-10-01 | Sell | 50,000 | $20.70 | 1,035,000 |
|
Sagent Pharmaceuticals Inc SGNT
common stock
|
2013-09-30 | Sell | 28,872 | $20.46 | 590,721 |
|
Sagent Pharmaceuticals Inc SGNT
common stock
|
2013-09-30 | Sell | 25,000 | $20.38 | 509,500 |
|
Sagent Pharmaceuticals Inc SGNT
common stock
|
2013-09-27 | Sell | 10,000 | $20.60 | 206,000 |
|
Sagent Pharmaceuticals Inc SGNT
common stock
|
2013-09-27 | Sell | 31,300 | $20.52 | 642,276 |
|
Sagent Pharmaceuticals Inc SGNT
common stock
|
2013-09-26 | Sell | 67,965 | $20.37 | 1,384,447 |
|
Sagent Pharmaceuticals Inc SGNT
common stock
|
2013-09-25 | Sell | 33,431 | $21.22 | 709,406 |
|
Sagent Pharmaceuticals Inc SGNT
common stock
|
2013-09-24 | Sell | 14,693 | $21.50 | 315,900 |
| showing 20 of 24 most recent transactions | |||||
| Related Firms | State | AUM |
|---|---|---|
|
Morgan Stanley Smith Barney LLC
✚
|
NY | 1,961.89 B |
|
Morgan Stanley Investment Management Inc
✚
|
NY | 702.25 B |
|
Morgan Stanley Investment Management Limited
✚
|
174.54 B | |
|
Morgan Stanley AIP GP LP
✚
|
PA | 40.85 B |
|
MS Capital Partners Adviser Inc
✚
|
NY | 38.76 B |
|
Morgan Stanley Infrastructure Inc
✚
|
NY | 15.97 B |
|
MSREF Real Estate Advisor Inc
✚
|
NY | 15.77 B |
|
Morgan Stanley Investment Management Company
✚
|
10.94 B | |
|
Morgan Stanley Private Equity Asia Inc
✚
|
NY | 1,864.3 M |
|
MSRESS III Manager LLC
✚
|
NY | 39.6 M |
|
Morgan Stanley Smith Barney Venture Services LLC
✚
|
NY | |
|
MSREF V LLC
✚
|
NY | |
|
Morgan Stanley Real Estate Advisor Inc
✚
|
NY |
| Comparable Firms | State | AUM |
|---|---|---|
|
Mai Capital Management LLC
✚
|
OH | 52.10 B |
|
SCS Capital Management LLC
✚
|
MA | 48.65 B |
|
Abrdn Inc
✚
|
PA | 41.48 B |
|
Strategic Investment Management LLC
✚
|
VA | 35.51 B |
|
Luther King Capital Management Corporation
✚
|
TX | 31.50 B |
|
Tiedemann Advisors LLC
✚
|
NY | 31.01 B |
|
Waverly Advisors LLC
✚
|
AL | 29.78 B |
|
Oxford Financial Group Ltd LLC
✚
|
IN | 23.33 B |
|
Jordan Park Group LLC
✚
|
CA | 23.26 B |
|
Ehrenkranz Partners LP
✚
|
NY | 21.54 B |